These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6805422)

  • 21. [A clinicobacteriologic study on clavulanic acid/amoxicillin in pediatric acute otitis media].
    Sugita R; Harada S; Deguchi K; Fujimaki Y; Naito M; Komatsu N; Nomura T; Okano K; Tanaka M; Shimizu K; Watanabe H; Kimura S; Yoshida Y; Senba T; Uchida T
    Jpn J Antibiot; 1999 Oct; 52(10):595-612. PubMed ID: 10638456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of faropenem and 20 other compounds against beta-lactamase-positive and -negative Moraxella catarrhalis and Haemophilus influenzae isolates and the effect of serum on faropenem MICs.
    Schmitz FJ; Boos M; Mayer S; Verhoef J; Milatovic D; Fluit AC
    J Antimicrob Chemother; 2002 Jan; 49(1):220-3. PubMed ID: 11751796
    [No Abstract]   [Full Text] [Related]  

  • 23. Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate.
    Thorburn CE; Molesworth SJ; Sutherland R; Rittenhouse S
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2796-801. PubMed ID: 9124843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro investigation of the indirect pathogenicity of beta-lactamase-producing microorganisms in the nasopharyngeal microflora.
    Kaieda S; Yano H; Okitsu N; Hosaka Y; Okamoto R; Inoue M; Takahashi H
    Int J Pediatr Otorhinolaryngol; 2005 Apr; 69(4):479-85. PubMed ID: 15763284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
    Pottumarthy S; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of amoxycillin/clavulanic acid (augmentin) against beta-lactamase-positive S. aureus, H. influenzae and B. catarrhalis in an in vitro kinetic model.
    Cooper CE; Slocombe B; White AR
    J Chemother; 1989 Jul; 1(4 Suppl):350-1. PubMed ID: 16312434
    [No Abstract]   [Full Text] [Related]  

  • 27. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries.
    Bandak SI; Turnak MR; Allen BS; Bolzon LD; Preston DA; Bouchillon SK; Hoban DJ
    Eur J Clin Microbiol Infect Dis; 2001 Jan; 20(1):55-60. PubMed ID: 11245326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation.
    Löwdin E; Cars O; Odenholt I
    Clin Microbiol Infect; 2002 Oct; 8(10):646-53. PubMed ID: 12390283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo synergism between amoxicillin and clavulanic acid against ampicillin-resistant Haemophilus influenzae type b.
    Yogev R; Melick C; Kabat WJ
    Antimicrob Agents Chemother; 1981 Jun; 19(6):993-6. PubMed ID: 6973952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor.
    Coleman K; Griffin DR; Page JW; Upshon PA
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1580-7. PubMed ID: 2817854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children.
    Pichichero ME; Doern GV; Kuti JL; Nicolau DP
    Paediatr Drugs; 2008; 10(6):391-7. PubMed ID: 18998749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The history and background of Augmentin.
    Rolinson GN
    S Afr Med J; 1982 Jul; 62(5 Spec No):3A-4A. PubMed ID: 6979804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Killing rate and growth rate comparison for newer beta-lactamase-stable oral beta-lactams against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
    Yourassowsky E; Van der Linden MP; Crokaert F
    Chemotherapy; 1992; 38(1):7-13. PubMed ID: 1618006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Haemophilus influenzae isolates with elevated MICs to amoxicillin/clavulanic acid.
    Jacobs MR; Bajaksouzian S
    Diagn Microbiol Infect Dis; 1997 Jul; 28(3):105-12. PubMed ID: 9294699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene.
    Torrico M; Aguilar L; González N; Giménez MJ; Echeverría O; Cafini F; Sevillano D; Alou L; Coronel P; Prieto J
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3699-706. PubMed ID: 17664320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [In vitro demonstration of a true post-beta-lactamases inhibitor effect (PLIE) of clavulanic acid on Klebsiella pneumoniae and Haemophilus influenzae].
    Murbach V; Dhoyen N; Linger L; Monteil H; Jehl F
    Pathol Biol (Paris); 1999 May; 47(5):462-8. PubMed ID: 10418019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative.
    Jones ME; Karlowsky JA; Blosser-Middleton R; Critchley IA; Thornsberry C; Sahm DF
    Int J Antimicrob Agents; 2002 Feb; 19(2):119-23. PubMed ID: 11850164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis.
    Alvarez S; Jones M; Holtsclaw-Berk S; Guarderas J; Berk SL
    Antimicrob Agents Chemother; 1985 Apr; 27(4):646-7. PubMed ID: 3873905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different {beta}-lactams: an in vitro pharmacodynamic approach.
    González N; Aguilar L; Alou L; Giménez MJ; Sevillano D; Torrico M; Cafini F; Coronel P; Prieto J
    J Antimicrob Chemother; 2009 Jun; 63(6):1215-22. PubMed ID: 19307171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.